Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Duligotuzumab), ADCC Enhanced (CAT#: AFC-TAB-H22)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized antibody to Human ERBB3

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location and Protein Expression
Normal Tissue
RNA Expression


  • Host Species
  • Human
  • Derivation
  • Humanized
  • Type
  • ADCC enhanced antibody
  • Specificity
  • ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) [Homo sapiens]
  • Species Reactivity
  • Human
  • Clone
  • Duligotuzumab
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF
  • Conjugate
  • Unconjugated
  • Generic Name
  • Duligotuzumab
  • Related Disease
  • Cancers

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.


  • Alternative Names
  • Duligotuzumab; ERBB3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); LCCS2, lethal congenital contracture syndrome 2; receptor tyrosine-protein kinase erbB-3; HER3; proto-oncogene-like protein c-ErbB-3;

Related Resources

  • Biosimilar Overview
  • Related Diseases
  • Related Signaling Pathways
Please refer to Duligotuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Duligotuzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.


Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "duligotuzumab"

Anti-Human ERBB3 Recombinant Antibody (Duligotuzumab) (TAB-H22)
Recombinant Humanized antibody to Human ERBB3

See other products for "Clone Duligotuzumab"

See other products for "ERBB3"

Single-domain Antibody


CAT Product Name Application Type
AGTO-L074E HRGβ2-PE immunotoxin Cytotoxicity assay, Functional assay

Chimeric Antibody

CAT Product Name Application Type
TAB-061CT Human Anti-ERBB3 Recombinant Antibody (TAB-061CT) Inhib, ELISA Chimeric (Rabbit/Human) antibody
TAB-061CT-S(P) Human Anti-ERBB3 Recombinant Antibody; scFv Fragment (TAB-061CT-S(P)) Inhib, ELISA Human scFv
TAB-061CT-F(E) Human Anti-ERBB3 Recombinant Antibody; Fab Fragment (TAB-061CT-F(E)) Inhib, ELISA Chimeric (Rabbit/Human) Fab

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-1179 Hi-Affi™ Rabbit Anti-ERBB3 Recombinant Antibody (clone DS1179AB) ICC, IF, WB Rabbit IgG

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H21 Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Duligotumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-422CQ Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Elgemtumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, BL ADCC enhanced antibody
AFC-TAB-189 Afuco™ Anti-ERBB3 Recombinant Antibody (AFC-TAB-189), ADCC Enhanced IP, IF, FuncS, FC, Neut, ELISA Human IgG1, κ
AFC-TAB-892 Afuco™ Anti-ERBB3 ADCC Recombinant Antibody (Seribantumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody

Submit a review or a question
There are currently no Customer reviews or questions for AFC-TAB-H22. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
    Go to compare

    Go to compare